Addressing hypersensitivity reactions induced by Daratumumab: A review of management approaches and preventive measures

---

Review Article

Author Details : Rose Mariya*, Basil Cheriyan

Volume : 10, Issue : 3, Year : 2023

Article Page : 239-244

https://doi.org/10.18231/j.ijpo.2023.053

Suggest article by email

Get Permission

---

Abstract

Daratumumab is a novel and remedial monoclonal antibody with broad-spectrum killing activity. It has shown a favorable safety profile as monotherapy in cases with relapsed/refractory multiple myeloma. Daratumumab along with its remedial benefits is associated with a range of Adverse Drug Reactions (ADRs) most importantly Hypersensitivity reactions that can significantly impact patient outcomes and health-related quality of life. The standard of care can be maintained by administering pre-infusion prophylactic medications and also by optimizing the Daratumumab infusions. The review focuses on the adverse drug reactions induced by Daratumumab, various preventative measures, and management strategies opted for curbing the Daratumumab-mediated infusion-related hypersensitivity reactions.
 

Keywords: Daratumumab, Hypersensitivity, Infusion­mediated reactions, Monoclonal antibody, Multiple myeloma

How to cite : Mariya R, Cheriyan B, Addressing hypersensitivity reactions induced by Daratumumab: A review of management approaches and preventive measures. Indian J Pathol Oncol 2023;10(3):239-244

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.